New drug strategy aims to shrink lung tumors before surgery
NCT ID NCT05206812
Summary
This study is testing if giving an immunotherapy drug called durvalumab before and after surgery can help control non-small cell lung cancer. It involves 25 patients with operable cancer. The main goal is to see how much the drug shrinks the tumor before it is removed and to understand how the patient's immune system responds to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.